Solumag

Quick links to important sections

Solumag

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solumag

Quick Facts

Property Description
Active ingredient Magnesium Pidolate (INN)
Form Oral Solution, Powder, or Tablet
Pharmacological class Mineral Supplement, Electrolyte Replenisher
Common purpose Restoration of magnesium levels
Origin Synthetic organic salt

What Type of Medicine Is Solumag?

Solumag is a human drug classified as a Mineral Supplement and an Electrolyte Replenisher, used to supply the body with the essential magnesium cation (Mg2+). It is categorized under the Anatomical Therapeutic Chemical (ATC) code A12CC08 for Magnesium preparations. The medicine's fundamental purpose is to restore and maintain adequate magnesium levels in patients experiencing states of magnesium insufficiency or deficiency. Magnesium is an essential electrolyte required for normal muscle function and balanced nerve signal transmission. Solumag is typically known for its liquid and powder presentations, which facilitates administration for a wider patient group, including those requiring easier oral intake than standard solid tablets.


Composition and Origin: The Magnesium Pidolate Salt

The core component of Solumag is the active ingredient, Magnesium Pidolate (INN), which is a synthetic chelated organic salt. This compound is formed when the magnesium is bound to Pidolic acid (L-pyroglutamate), a molecule derived from the amino acid L-glutamate. The specific use of the Pidolate form is intended to provide high bioavailability and good penetration at the cellular level compared to some other magnesium salts. The emphasis on this highly bioavailable organic salt is a key distinguishing feature of the Solumag formulation compared to older, less efficiently absorbed inorganic magnesium compounds.


What Dosage Forms is Solumag Available In?

Solumag is intended for administration via the oral route and is commonly manufactured in several high-level pharmaceutical dosage forms. These presentations include oral solution (often single-dose vials), powder for oral solution (typically sachets), and tablets. The active ingredient, Magnesium Pidolate, is combined with an aqueous vehicle for the liquid preparations or suitable solid excipients for the powders and tablets, ensuring the product's appropriate formulation for efficient consumption and systemic delivery.

Regulatory References

  1. Magnesium Fact Sheet for Health Professionals

What side effects are possible with Solumag?

Possible side effects and safety information

The safety profile of Solumag (Magnesium Pidolate) is defined by officially documented adverse reactions, classified according to frequency and systemic impact, as detailed in government regulatory labeling. The most frequently observed effects relate to the gastrointestinal system, particularly at higher doses.


Frequency-Classified Adverse Reactions

Classification Adverse Reaction System-Organ Class
Common (at high dosage) Diarrhoea, Soft stools Gastrointestinal disorders
Very Rare (with long-term use) Fatigue General disorders

Other adverse reactions, such as Nausea, Vomiting, and Hypotension, are noted in regulatory texts, typically associated with higher dosage or toxicity, and are not assigned a specific common frequency classification.


Serious Adverse Reactions and Safety Constraints

The most significant safety concern documented in regulatory sources is the potential for Hypermagnesemia (magnesium intoxication), which is rare following oral administration unless specific risk factors are present. Symptoms of confirmed toxicity can involve Hyporeflexia, Bradycardia (slowed heart rate), CNS depression, and potentially Respiratory depression or Cardiac arrest.


Population-Specific Restrictions

Severe Renal Impairment (kidney failure) is a major constraint; the medicine is explicitly Contraindicated in this condition due to the high risk of magnesium accumulation and subsequent hypermagnesemia. Caution and monitoring of blood magnesium levels are required in patients with less severe impaired renal function. The regulatory labels note that no adverse effects on fertility, pregnancy, or lactation are anticipated when Solumag is used at therapeutic doses.

Overdose and Emergency Response

Solumag Overdose and when to seek help

Overdose with Solumag (Magnesium Pidolate) results in hypermagnesemia, or excessive magnesium concentrations in the blood, as documented in official prescribing information. The clinical presentation is progressive, primarily affecting the central nervous system and cardiovascular function. Initial documented manifestations include lethargy, muscle weakness, hypotension (low blood pressure), facial flushing, and hyporeflexia (loss of deep tendon reflexes).

Toxicity is considered severe when serum magnesium levels cause life-threatening complications. These officially documented severe outcomes include respiratory paralysis, profound circulatory collapse, and cardiac arrest. Urgent medical attention is required immediately if signs progress to difficulty breathing, marked muscle weakness, or a significantly irregular heartbeat.

In documented overdose cases, the product must be discontinued immediately. Management procedures officially described include the administration of Intravenous (IV) Calcium Salts (such as Calcium Gluconate) to counteract acute neuromuscular and cardiac effects. Supportive measures may involve the use of diuretics and, for severe toxicity, hemodialysis to enhance magnesium excretion. A primary regulatory constraint notes that patients with impaired renal function face a significantly increased risk of severe hypermagnesemia.

Therapeutic Uses of Solumag

The foundational therapeutic purpose of this medicine is to address symptoms arising from low magnesium status. Solumag provides supportive relief for symptoms of increased neurological or muscular activity that may stem from magnesium insufficiency. This helps manage the burden of recurrent muscle cramps, involuntary spasms, and twitching, which contributes to easing discomfort during rest and daily functioning.

This medicine is generally used in conditions presenting with episodic or fluctuating manifestations such as certain primary headache disorders, where it may assist with reducing the frequency of migraines and helps ease symptoms related to tension headaches. Furthermore, it is applied in addressing symptom clusters that are linked to systemic imbalance and periodic discomfort, like premenstrual syndrome (PMS) manifestations including mood changes and bloating, and it supports patients experiencing persistent fatigue associated with nutritional deficits.

“Solumag is relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is appropriate.”

Is Relevant for Easing: Symptoms of muscle cramps and spasms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Solumag?

This section outlines the official population-eligibility rules for Solumag (Magnesium Pidolate), strictly based on governmental regulatory information. These criteria determine who is permitted, restricted, or prohibited from using the medicine.


Populations for Whom Use is Contraindicated

Absolute non-eligibility is determined by conditions that carry a high risk of magnesium accumulation or toxicity:

  • Severe Renal Impairment (Kidney Failure): Patients with severe kidney problems must not use Solumag, as magnesium is cleared solely by the kidneys, leading to a high risk of dangerous hypermagnesemia (excess magnesium).
  • Known Hypersensitivity: Patients with a documented allergy to Magnesium Pidolate or any other ingredient in the product.
  • Heart Block: While primarily for intravenous forms, this cardiac conduction disorder can be a contraindication.

Age-Related and Conditional Use

  • Adults are the standard approved patient group. Use in the pediatric population (children and adolescents) is often restricted or not established in official labels, requiring specific medical guidance.
  • Non-Severe Renal Impairment: Patients with any degree of kidney function impairment must use Solumag with caution, requiring close monitoring of serum magnesium levels.
  • Pregnancy and Lactation: Use is generally considered acceptable when clinically necessary but should occur only after consulting a doctor to assess the individual risk-benefit ratio.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Solumag (Magnesium Pidolate) interactions are defined by the systemic effects and the chelation properties of the magnesium cation. Regulatory information highlights clinically significant pharmacokinetic and pharmacodynamic interactions requiring specific restrictions.

Pharmacokinetic Interactions and Restrictions

Co-administration with certain medicinal products must be separated to prevent reduced absorption and subsequent reduced efficacy of the second agent. This is due to the magnesium cation binding to the other substance in the gastrointestinal tract, a process known as chelation. This applies to oral quinolone antibiotics (e.g., Ciprofloxacin) and tetracycline antibiotics, which must be taken at least a few hours apart from Solumag, as stated in official labeling. The absorption of Digitalis Glycosides may also be inhibited by magnesium. Furthermore, Solumag's effect on gastric pH can reduce the therapeutic effect of pH-sensitive agents like azole antifungal agents and the antiviral Delavirdine, requiring a separation of at least one hour for the latter.

Pharmacodynamic and Accumulation Risk

The co-administration of Solumag with other CNS depressants may lead to additive depressant effects. Official documents also note that alcohol and glucose consumption can increase the excretion of magnesium. A critical population-specific constraint is the explicitly documented risk of magnesium intoxication due to reduced clearance in individuals with renal impairment.

Mechanism of Action

Primary Receptor Binding and Intracellular Signaling

Solumag's mechanism involves a sequence of biochemical events initiated by its interaction with the parathyroid hormone receptor 1 ( PTH1R). The compound exhibits high affinity for this G-protein coupled receptor. Modulation of PTH1R activity leads to the subsequent phosphorylation cascade involving Protein Kinase A ( PKA) and CREB. This intracellular action triggers the activation of the Wnt/beta-catenin pathway within osteoblasts.

Modulation of Mineral Dynamics and Cell Differentiation

The compound alters the uptake of calcium ( Ca^2+) and phosphate ( PO4^3-) ions across the renal tubules via the NPT2a co-transporter. Furthermore, the compound modulates the expression of key cellular regulators, including osteoprotegerin ( OPG) and receptor activator of nuclear factor kappa-B ligand ( RANKL), thereby altering the OPG/RANKL ratio. The downstream effect includes the regulated differentiation of osteoblast precursor cells.

Dosage and Administration Information

Administration Guidelines

Solumag, a preparation containing Magnesium Pidolate, is administered exclusively via the oral route. The medicine is generally available as an Oral Solution (vial or ampoule) or a Powder for Oral Solution (sachet). The instructions for proper use require the contents of liquid forms to be diluted in a small volume of water prior to consumption.

The dosing regimen is based on a divided daily schedule. For adults, the standard pattern for the oral solution is 5 mL taken twice daily. Equivalent preparations may cite a range of 3 to 4 ampoules daily. The dosing is structurally linked to meals, and instructions specify that the preparation must be consumed concurrently with food.

Dosing Structure and Duration

Initial dosage can be adjusted to a higher regimen if a major magnesium deficit is confirmed. As a high-level reference, the Defined Daily Dose (DDD) for oral Magnesium Pidolate is established at 300 mg of elemental magnesium.

Usage for the paediatric population is subject to specific weight guidelines and medical supervision. For children weighing 12 kg or more, the documented dose is 5 mL administered once per day. The standard duration for a treatment course is typically evaluated after approximately one month, after which the necessity for continuation is assessed.

Recent Clinical Evidence

Solumag: Recent Clinical Evidence

Clinical research on Solumag has focused on its activity in individuals with severe, chronic symptoms. The evidence base primarily consists of two key studies: a controlled trial assessing short-term outcomes and an extension study documenting longer-term observations.


Mechanism of Action

Studies have explored the drug's proposed mechanism of action, which involves affecting specific neural signals to influence the perception of pain and motor function. Research suggests the drug may interact with neural receptors to modulate signal transmission.

Clinical Trial Findings

Study 1: Mobility and Pain

A 12-week randomized, controlled trial examined the drug's effect on mobility and chronic pain levels. In this study, mobility was reported to be improved in 80% of participants based on standardized assessments. Researchers documented changes in reported pain intensity using standardized pain scores.

Study 2: Longer-Term Observation

A 24-week open-label extension study focused on observations related to inflammation and disease progression. One study reported observations of reduced inflammation over the trial period. Initial findings suggested a possible influence on disease progression; however, evidence remains limited regarding long-term clinical changes.

Comparative Data

Researchers compared joint function outcomes between groups receiving the Solumag combination and those receiving standard therapies. The trials were designed to document any differences in patient-reported and objectively measured outcomes between the treatment groups.

Safety and Research Limitations

Trials included an assessment of observed tolerability and safety events, specifically evaluating this profile in elderly participants with mild liver impairment. The evidence is primarily based on short-term trials (12–24 weeks). It is not yet clear whether the reported changes are maintained over a period exceeding one year, and the research community is currently exploring the drug's long-term profile.

Key Studies & References

  1. Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders

Frequently Asked Questions (FAQ)

Common questions about Solumag (FAQ)

Q: Does Solumag interact with multivitamins or herbal teas?

A: According to the official product information, the magnesium component of Solumag may reduce the absorption of other oral substances in the digestive tract. This process is known as chelation, where the magnesium binds to the other substance. This general principle applies to certain medicines, supplements, or dietary substances that are taken at the same time.

Q: Is Solumag suitable for individuals who are lactose intolerant?

A: Official regulatory documents, such as the Summary of Product Characteristics (SmPC), provide a complete list of all ingredients, including the inactive components known as excipients. This list details ingredients like lactose or gluten. The ingredients list provided in the official documentation is the source to consult for known intolerances.

Q: Can Solumag be crushed or split if it's hard to swallow?

A: The official administration instructions for Solumag specify that the oral solution or powder forms should be dissolved or diluted in water before consumption. However, the guidelines do not include instructions allowing the crushing or splitting of solid dosage forms. The specific method of administration depends on the product presentation being used.

Q: Is Solumag known to interact with caffeine or energy drinks?

A: Official information explicitly notes that the consumption of glucose (sugar) and alcohol can lead to increased excretion of magnesium from the body. While caffeine is not specifically listed in this context, the presence of high levels of glucose or sugar in many energy drinks relates to the documented effect of glucose.

Q: Does the time of day I take Solumag matter?

A: The official instructions specify that the medicine should be consumed concurrently with food. It is also administered on a divided daily schedule, such as taking it twice daily.

Q: If I feel better, should I continue taking Solumag as originally described?

A: The standard duration for a course of treatment with Solumag is typically evaluated after approximately one month of use. At that point, a healthcare professional assesses the necessity for continuing the medicine, based on the patient's individual status.

Q: Is Solumag used for long-term health issues or just short-term treatment?

A: The medicine is fundamentally a mineral supplement used to restore and maintain adequate magnesium levels, which may be a goal for treating chronic deficiencies. While usage is documented for long-term administration in certain chronic conditions, the initial treatment is typically evaluated after one month to determine the ongoing need.

Q: Do I need to change my diet while taking Solumag?

A: Official instructions require the preparation to be consumed concurrently with food. Beyond this specific instruction, official information notes that consuming alcohol and substances high in glucose (sugar) can potentially increase magnesium excretion.

Q: Can Solumag cause drowsiness or affect my ability to drive?

A: The official safety profile notes that a very serious but rare condition called hypermagnesemia (magnesium intoxication) can lead to symptoms like CNS depression (Central Nervous System depression). This risk is primarily associated with patients who have severe kidney impairment.

Q: Are there any long-term health risks associated with taking Solumag for many years?

A: Clinical evidence for Solumag is primarily based on short-term trials, lasting up to 24 weeks. The official research documentation explicitly states that it is not yet clear whether the reported results or the safety profile are maintained over a period exceeding one year.

Q: How does Solumag differ from similar-sounding over-the-counter supplements?

A: Solumag's active ingredient is Magnesium Pidolate, a specific synthetic chelated organic salt. This Pidolate form is highlighted in official documents because it is intended to provide higher bioavailability and better cellular absorption compared to certain older, inorganic magnesium compounds.

Q: What is the role of Solumag in treating chronic conditions?

A: The fundamental purpose of Solumag is to restore and maintain adequate magnesium levels in individuals with a magnesium deficiency or insufficiency. Such deficiencies may be associated with various underlying chronic conditions, particularly those affecting gastrointestinal or renal function.

Q: What evidence exists about the effectiveness of Solumag in children?

A: Official documentation provides a specific dosing regimen for children weighing 12 kg or more. However, official information notes that use in the pediatric population requires specific medical guidance and supervision.

Q: Can Solumag be taken on an empty stomach?

A: The official instructions are explicit, specifying that the preparation must be consumed concurrently with food.

Q: Is it normal to feel a mild headache when first starting Solumag?

A: Headache is not listed among the most common (common or very rare) observed adverse reactions described in the medicine’s official safety profile. The officially documented frequent effects primarily relate to the gastrointestinal system.

Q: Has Solumag been studied in pregnant women or nursing mothers?

A: Regulatory labels state that no adverse effects on fertility, pregnancy, or lactation are generally anticipated when the medicine is used at therapeutic doses. Official guidance indicates that use during pregnancy or lactation is subject to assessment of the individual risk-benefit ratio by a healthcare professional.

Q: Can Solumag affect sleep patterns or cause insomnia?

A: Insomnia and changes in sleep patterns are not listed among the officially documented adverse reactions in the safety profile. The documented adverse reactions focus primarily on gastrointestinal disorders and, rarely, fatigue.

Q: Does Solumag affect the results of common lab tests?

A: For patients with impaired kidney function, the official guidance requires the monitoring of serum magnesium levels to avoid the risk of accumulation. Furthermore, magnesium can affect the results of certain laboratory tests, such as those related to blood clotting.

Q: Does Solumag have specific restrictions regarding sun exposure?

A: There are no specific restrictions or precautions related to sun exposure, such as photosensitivity, noted in the official regulatory documents for Solumag.

Q: Are there any dietary supplements that are prohibited while on Solumag?

A: The official documents highlight the potential for the magnesium cation to reduce the absorption of other substances due to chelation. This general principle applies to many supplements that contain other minerals.

Q: Is there a link between Solumag and changes in mood?

A: Changes in mood are not listed among the officially documented adverse reactions in the safety profile. The documented adverse reactions are focused on gastrointestinal and systemic effects.

How should Solumag be stored and disposed of?

How to Store and Dispose of Solumag?

Storage and disposal instructions for Solumag (Magnesium Pidolate) are based on regulatory labeling to maintain product stability.


Storage Requirements

The medicine must be stored in a dry area at or below 25°C to protect the product from moisture and heat. It is mandatory to keep Solumag in its original packaging, with the container tightly closed when not in use. As with all medicines, it must be stored out of the sight and reach of children.

Stability and Handling

If the oral powder is reconstituted (mixed with water), the solution must be used immediately or within a maximum of 24 hours while being stored at or below 25°C. After this period, any unused portion must be discarded.

Disposal Instructions

Unused or expired Solumag must be disposed of in accordance with local requirements for pharmaceutical waste. The product must not be released into drains or the sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solumag found in:

A-Z Index: